I-Wholeleale Oeete China CE imakishwe i-SARS Antigen Thid Colloidal igolide

Inkcazo emfutshane:


  • Ixesha lovavanyo:Imizuzu eli-10-15
  • Ixesha elifanelekileyo:Inyanga engama-24
  • I-Accuranity:Ngaphezulu kwe-99%
  • Ukucaciswa:I-1/6 yovavanyo / ibhokisi
  • Iqondo lokugcina:2 ℃ -30 ℃
  • :
  • Iinkcukacha zemveliso

    Iimpawu zeMveliso

    Inkampani yethu inyanzelisa yonke imigaqo-nkqubo yemveliso ye "Imveliso esemgangathweni ikwisiseko sexhoba lokusinda; Inzaliseko yomthengi iya kuba yeyona ndawo ibonakalayo kunye nokuphela kwenkampani; Ukuphuculwa okungapheliyo kukufuna okungapheliyo 'kunye nenjongo engaguqukiyo' yegama lokuqala, shopper kuqala "kwi-Oetem Oeete Chest rallodal igolide e-Antigen yovavanyo kunye nomgangatho ophezulu wokugcina yonke Ukukhula komgangatho walo mzi mveliso kwaye ufezekise ulwaneliseko lwakho ngempumelelo. Ukuba unomdla ngaphakathi kwezisombululo zethu, nceda unxibelelane nathi ngokukhululekileyo.
    Inkampani yethu inyanzelisa yonke imigaqo-nkqubo yemveliso ye "Imveliso esemgangathweni ikwisiseko sexhoba lokusinda; Inzaliseko yomthengi iya kuba yeyona ndawo ibonakalayo kunye nokuphela kwenkampani; Ukuphuculwa okungapheliyo kukufuna okungapheliyo kwabasebenzi "kunye nenjongo engaguqukiyo" yegama lokuqala, shopper "China SARS Antign Uvavanyo, I-SARS-C0V2 Uvavanyo, Ngoku siye sacinga ngokunyaniseka ukuba sinike iarhente ye-brand kwiindawo ezahlukeneyo kunye nearhente zethu zearhente zethu zenzuzo yenzuzo yeyona nto ibaluleke kakhulu esiyikhathaleleyo. Wamkelekile bonke abahlobo kunye nabathengi ukuba bazimanye. Sele sikulungele ukwabelana ngeBhunga le-Win-Win.
    I-cea

    cal_conew1

     

    Iimveliso Inkcazo ikhowudi iyunithi Uluhlu lwelayini Uluhlu lwereferensi Uluhlu lwelayini
    Ikhithi yokufumana isifo se-carcinotic antign I-25t / ibhokisi I-cea Ng / ml 2-500 <5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


  • Ngaphambili:
  • Okulandelayo: